NCT03895359View on ClinicalTrials.gov

Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

May 27, 2019

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions
Hepatocellular Carcinoma
Interventions
RADIATION

Stereotactic Body Radiation

For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.

DRUG

Transarterial Chemoembolization

Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.

Trial Locations (1)

N6A 5W9

RECRUITING

London Health Sciences Centre, London Regional Cancer Program, London

Sponsors

Collaborators (1)

CancerCare Manitoba
All Listed Sponsors
collaborator

CancerCare Manitoba

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT03895359 - Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma | Biotech Hunter | Biotech Hunter